Evidence map›Paper›PMID 31856918›Full record

ArticleJournal for immunotherapy of cancer2019

The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC).

Brian I Rini, Dena Battle, Robert A Figlin, Daniel J George, Hans Hammers, Tom Hutson, Eric Jonasch, Richard W Joseph, David F McDermott, Robert J Motzer and 8 more

Open access · goldAbstract readConsensus Statement
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal for immunotherapy of cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 150 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
150citing papers in PubMed, 2 pooled it
17.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

150 citing papers in PubMed, 2 syntheses or guidelines pooled it, 259 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Nivolumab in previously treated advanced gastric cancer (ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumab.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2021
    Trial
  6. Trial
  7. Trial
  8. Trial
  9. Review
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Immune Checkpoint Inhibitors in Clear Cell Renal Cell Carcinoma (ccRCC).International journal of molecular sciences · 2025
    Review
  17. Review
  18. Article
  19. Article
  20. Article

90 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 14 institutions in 1 country.

Brian I RiniCleveland Clinic Taussig Cancer Center, Cleveland, OH, USA.
Dena BattleKCCure, Leesburg, VA, USA.
Robert A FiglinCedars-Sinai Medical Center, Los Angeles, CA, USA.
Daniel J GeorgeDuke University School of Medicine, Durham, NC, USA.
Hans HammersUT Southwestern, Dallas, TX, USA.
Tom HutsonCharles A. Sammons Cancer Center, Baylor, Dallas, TX, USA.
Eric JonaschMD Anderson Cancer Center, Houston, TX, USA.
Richard W JosephMayo Clinic, Jacksonville, FL, USA.
David F McDermottBeth Israel Deaconess Medical Center, Boston, MA, USA.
Robert J MotzerMemorial Sloan-Kettering Cancer Center, New York, NY, USA.
Sumanta K PalCity of Hope, Duarte, CA, USA.
Allan J PantuckUCLA School of Medicine, Los Angeles, CA, USA.
David I QuinnNorris Comprehensive Cancer Center, Los Angeles, CA, USA.
Virginia SeeryBeth Israel Deaconess Medical Center, Boston, MA, USA.
Martin H VossMemorial Sloan-Kettering Cancer Center, New York, NY, USA.
Christopher G WoodMD Anderson Cancer Center, Houston, TX, USA.
Laura S WoodCleveland Clinic Taussig Cancer Center, Cleveland, OH, USA.
Michael B AtkinsGeorgetown, Lombardi Comprehensive Cancer Center, Research Building, Room E501 3970 Reservoir Road NW, Washington, DC, 20057, USA. mba41@Georgetown.edu.ORCID 0000-0003-3901-9924
Beth Israel Deaconess Medical Center · USCleveland Clinic · USMemorial Sloan Kettering Cancer Center · USThe University of Texas MD Anderson Cancer Center · USCedars-Sinai Medical Center · USCity of Hope · USDuke University · USGeorgetown University · USK2M (United States) · USSouthwestern Medical Center · USTexas Oncology · USUniversity of California, Los Angeles · USUSC Norris Comprehensive Cancer Center · USWinnMed · US

Funding

Women's Cancer Research ProgramP30CA014236 · NCI · DUKE UNIVERSITY · PI DONNA NIEDZWIECKI · 1985 to 2026
$174.8M
NCI NIH HHS P30 CA014236
6 · The paper itself

Abstract

The approval of immunotherapeutic agents and immunotherapy-based combination strategies in recent years has revolutionized the treatment of patients with advanced renal cell carcinoma (aRCC). Nivolumab, a programmed death 1 (PD-1) immune checkpoint inhibitor monoclonal antibody, was approved as monotherapy in 2015 for aRCC after treatment with a VEGF-targeting agent. In April 2018, the combination of nivolumab and ipilimumab, a CTLA-4 inhibitor, was approved for intermediate- and poor-risk, previously untreated patients with aRCC. Then, in 2019, combinations therapies consisting of pembrolizumab (anti-PD-1) or avelumab (anti-PD-ligand (L) 1) with axitinib (a VEGF receptor tyrosine kinase inhibitor) were also approved to treat aRCC and are likely to produce dramatic shifts in the therapeutic landscape. To address the rapid advances in immunotherapy options for patients with aRCC, the Society for Immunotherapy of Cancer (SITC) reconvened its Cancer Immunotherapy Guidelines (CIG) Renal Cell Carcinoma Subcommittee and tasked it with generating updated consensus recommendations for the treatment of patients with this disease.

Indexed as

Biomarkers, TumorMolecular Targeted TherapyAntineoplastic Agents, ImmunologicalCarcinoma, Renal CellDisease ManagementHumansImmunotherapyKidney NeoplasmsNeoplasm StagingPractice Guidelines as TopicAntineoplastic Agents, ImmunologicalBiomarkers, TumorGuidelinesImmune checkpoint inhibitor (ICI)ImmunotherapyKidney cancerRenal cell carcinoma (RCC)

Identifiers

PMID31856918
PMCPMC6924043
OpenAlexW2994968455

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.